CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has retained the services of Skyline Corporate Communications Group, LLC (“Skyline”) to manage its investor relations and corporate communications activities within the financial community.
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/The%20sign%20for%20Marvell%20Technology%20out%20front%20of%20a%20corporate%20office%20by%20Valeriya%20Zankovych%20via%20Shutterstock.jpg)
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
